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Purpose: To investigate the structural features that influence the antinociceptive activity of 
thymoquinone and their structural analogues.  
Methods: The quinones were prepared by an oxidation procedure using molecular oxygen and catalysis 
with [CoII(salen)] from the respective phenols. The antinociceptive activity of para-benzoquinones (10 
mg/kg, ip) was evaluated using formalin test in mice. Vehicle (5 % Tween 80) or morphine (10 mg/kg) 
were used as control group and standard drug, respectively. The amount of time spent licking the 
injected paw was considered as the nociceptive response. 
Results: Among the compounds tested, five para-benzoquinones showed antinociceptive activity. The 
2-isopropyl-para-benzoquinone presented the highest potency in first and second phases and produced 
a near-maximal inhibition (p < 0.001) in the formalin test, similar to morphine (p < 0.001).  
Conclusion: Our experimental results show that by appropriate structural modification of para-
benzoquinones it may be possible to develop novel analgesic drugs. 
 
Keywords: Quinones, Antinociceptive activity, Analgesic, Central nervous system, Structure-activity 
relationship, Medicinal plant. 
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INTRODUCTION 
 
Although a considerable number of analgesic 
drugs are available for the treatment of pain, 
medicinal plants are widely investigated as a 
rich source of natural components capable of 
exerting peripheral and central analgesic 
activity, but with the potential to be devoid of 
undesirable side effects and addictive 
properties displayed by conventional 
analgesic drugs. Furthermore, some 
chemical constituents of medicinal plants are 
candidates for analgesic drugs [1,2]. 
 
Para-benzoquinones are potentially derivable 
by oxidation of suitable phenolic compounds. 
Many of these para-benzoquinones have 
important biochemical functions in electron 
transport systems for respiration or 
photosynthesis. Natural products containing 
the para-benzoquinone sub-structural unit are 
many, for example, vitamins K1 and K2, co-
enzyme Q (ubiquinone), and also occur in 
many terpenes [3].  
 
The pharmacological properties attributed to 
naturally occurring quinones are thus well 
established. For example, thymoquinone, the 
principal active constituent of Nigella sativa 
seeds, presents antinociceptive activity [4]. 
Therefore, these facts led us to compare the 
antinociceptive activity of six structurally-





Solvents and reagents were used as received 
from the manufacturer, or purified, when 
required, by standard procedures. The six 
phenols and N,N′-bis(salicylidene) 
ethylenediaminocobalt(II)[CoII(salen)] employ-
ed were commercially available products 
(Aldrich) and used as obtained 
 
General procedure for metal complex-
catalyzed oxidation 
 
Phenol (1.0 mmol) was dissolved in 
dimethylformamide (DMF, 5 mL) and oxygen 
was bubbled into the reaction mixture for a 
few minutes by way of a rubber septum and a 
syringe needle, and then an oxygen 
atmosphere was maintained with a balloon by 
filling a toy balloon, and coupling to the same 
syringe inlet. CoII (salen) catalyst (0.0195 g, 
0.06mmol) was added, and the reaction 
mixture stirred at room temperature for 3 h. 
More of the catalyst (0.0195 g, 0.06 mmol) 
was added and the reaction mixture stirred 
for another 3 h at room temperature. The 
process was repeated once more, for a total 
addition of 0.18 mmol (0.0585 g) catalyst and 
a total reaction time of 24 h. Ether (20 mL) 
was added and the black mixture washed 
with 0.1 molL-1 HCl (2 × 10 mL), water and 
brine. The ethereal solution was dried over 
anhydrous magnesium sulfate (MgSO4) and 
the solvent evaporated. The residue was 
purified by sublimation (or by flash column 
chromatography when necessary, using as 
eluent a mixture of 9:1 hexane:ethyl acetate) 
[5,6]. 
 
Nuclear Magnetic Resonance (NMR) and 
melting point determinations 
 
1H and 13C NMR spectra were obtained on a 
Bruker DRX-400 NMR spectrometer at 400 
and 100 MHz respectively. Chemical shifts 
were expressed in ppm downfield from a 
tetramethylsilane internal standard. Melting 
point was determined on a Micro Química 





Male Swiss mice (28 – 34 g) were obtained 
from the vivarium Prof. Dr. ThomasGeorge of 
LTF/UFPB, in which they were created. The 
animals were maintained at constant room 
temperature (23 ± 1 oC) and on a 12/12 h 
light-dark cycle (light from 06:00 to 18:00), 
with free access to food and water. All 
behavioral observations were conducted 
between 08:00 and 12:00 h and the study 
was approved by the Ethics Committee for 
the Care and Use of Animals of the Federal 
University of Paraiba (Comitê de Ética em 
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Pesquisa Animal do Laboratório de 
Tecnologia Farmacêutica - CEPA No 
0202/08) [7]. 
 
Formalin test  
 
The animals received an injection of 20 µl of 
2.5 % formalin (0.92 % formaldehyde diluted 
in normal saline) in the subplantar area of the 
right hind paw. The duration of paw licking 
was measured in the periods 1 - 5 min (first 
phase) and 15 - 30 min (second phase) after 
the formalin injection. The amount of time 
spent licking the injected paw was considered 
as the nociceptive response. Animals were 
divided into eight groups (n = 8) and 
subjected to intraperitoneal (ip) administration 
of para-benzoquinones 1-6 (10 mg/kg, ip), 
vehicle (5 % Tween 80) or morphine (10 
mg/kg), respectively, 30 min prior to the 




Statistical analysis was performed using 
analysis of variance (ANOVA), followed by 
Tukey’s multiple comparison test. A 
probability level of 0.05 was regarded as 




The results in respect of the prepared 
quinones are shown in the Scheme 1 and 
Table 1. while antinociceptive activity data 


















1 (30%)                 2 (54%)                     3 (34%)
4 (95%)                 5 (90%)   6 (93%)    
 




Previous studies showed that Nigella sativa 
seeds oil and its major component, 
thymoquinone, have significant 
antinociceptive activity [4]. Assessment of 
this pharmacological activity with regard to 
para-benzoquinones using formalin test in 
mice was investigated in the present work. 
This test is a model of acute and tonic pain, 
being considered a more valid model for 
clinical pain than tests based on mechanical 
or thermal stimulation [8]. 
 
The first phase results from direct chemical 
stimulation of the nociceptive afferent fibers, 
mainly C fibers, and the release of substance 
P [14], and may be inhibited by centrally 
acting analgesics such as morphine. The 
second phase is a consequence of the action  
de Sousa et al 
Trop J Pharm Res, August 2012;11 (4): 608 
Table 1: Characterization data of prepared compounds 
 
Compound Physical and spectral data 
       1 
 
Yield: 30%; Mp oC: 110-114; Lit. Mp oC: 113-115 [10]; CAS 106-51-4; 1H NMR (CDCl3/TMS) 
, J(Hz): 6.79 (4H, s); 13C NMR (CDCl3/TMS) δ: 136.6, 187.2 
       2 Yield: 54%; Mp oC: 65–68; Lit. Mp oC: 67-70 [11]; CAS 553-97-9; 1H NMR (CDCl3/TMS) , 
J(Hz): 1.90 (3H,s), 6.62 (1H, s), 6.75 (1H, d, J=10.1 Hz), 6.77 (1H, d, J=10.1 Hz); 13C NMR 
(CDCl3/TMS) δ: 15.8, 133.3, 136.4, 136.5, 145.9, 187.5, 187.7 
       3 Yield: 34%; Mp oC: 57-60; Lit. Mp  oC: 54-58 [10]; CAS 15232-10-7; 1H NMR (CDCl3/TMS) , 
J(Hz): 1.14 (6H, d, J=6.8 Hz),  3.05 (1H, dhept, J=6.8; 1.1 Hz), 6.55 (1H, d, J=1.1 Hz), 6.73 
(1H, d, J=2.5 Hz), 6.74 (1H, d, J=2.5 Hz); 13C NMR (CDCl3/TMS) δ: 16.5, 26.2, 130.3, 135.9, 
137.0, 154.9, 187.1, 188.1 
       4 Yield: 95%; Mp oC: 69–72; Lit. Mp oC: 71–73 [12]; CAS 527-61-7; 1H NMR (CDCl3/TMS) , 
J(Hz): 2.10 (6H, d, J=1.0 Hz), 6.56 (2H, q, J=1.0 Hz); 13C NMR (CDCl3/TMS) δ: 15.9, 133.3, 
145.7, 187.1 
       5 Yield: 90%; Mp oC: 121-123; Lit. Mp oC: 124–125 [13]; CAS 137-18-8; 1H NMR (CDCl3/TMS) 
, J(Hz): 2.04 (6H, d, J=1,6Hz), 6.60 (2H, q, J=1,6Hz); 13C NMR (CDCl3/TMS) δ: 15.6, 133.3, 
145.7, 188.7 
       6 Yield: 93%; Mp oC: 47–48; Lit. Mp  oC: 45–47 [5]; CAS 490-91-5; 1H NMR (CDCl3/TMS) , 
J(Hz): 1.13 (6H, d, J=6.8Hz), 2.04 (3H, d, J=1.6Hz), 3.03 (1H, d hept, J=1.2 and 6.8Hz), 6.52 
(1H, d, J=1.2Hz), 6.59 (1H, q, J=1.6Hz); 13C NMR (CDCl3/TMS) δ: 15.3, 21.4, 26.5, 130.3, 



























Fig 1: Effect of para-benzoquinones 1-6 (10 mg/kg, ip) and morphine (10 mg/kg, ip) on licking time 
(formalin test) during the First Phase in mice. The values represent mean ± S.E.M. (n = 8); *p < 0.01, **p < 





























Fig 2: Effect of para-benzoquinones 1-6 (10 mg/kg, ip) and morphine (10 mg/kg, ip) on licking time 
(formalin test) during the Second Phase in mice. The values represent mean ± S.E.M. (n = 8); *p < 0.01, 
**p < 0.001 significantly different from control (vehicle)  
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of inflammatory mediators released locally, 
such as prostaglandins, serotonin, histamine, 
and bradykinin [15,16] and also from 
enhanced synaptic transmission in the spinal 
cord [17]. 
 
Among the compounds tested, five para-
benzoquinones were found to have 
antinociceptive activity (Figure 2). The 2-
isopropyl-para-benzoquinone (3) (isopropyl 
group at carbon 2), (p < 0.001), was the 
compound that presented the highest 
potency (Figure 1) and has effect in both 
phases. These results show that the mode of 
action of 3 is via central and peripheral 
pathways. In fact, this benzoquinone 
produced a near-maximal inhibition on the 
formalin test (p < 0.001), similar to morphine 
(p < 0.001) on second phase. The 
unsubstituted para-benzoquinone (1) (no 
alkyl groups) exhibited a similar effect to 3, 
but was less potent in the first phase (p < 
0.01). The other quinones were inactive in 
this phase. These data demonstrate that the 
absence of alkyl groups or the presence of a 
bulky alkyl group in the structure of para-
benzoquinones results in psychoactive 
compounds with antinociceptive activity. 
Interestingly, only compound 2 was inactive 
in the second phase. The other para-
benzoquinones showed significant 
antinociceptive effect (p < 0.001). Therefore, 
para-benzoquinones 4, 5, and 6 are 





An attempt has been made in this study to 
understand the structural relationship 
between para-benzoquinones and their 
analgesic-like effects. The results suggest 
that by appropriate structural modification of 
para-benzoquinones, it may be possible to 
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